# Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

> **NCT05201547** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 260 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Carboplatin-Paclitaxel
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT05201547
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-15
- **Primary completion:** 2026-04
- **Final completion:** 2029-10
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201547, "Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05201547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*